Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- , a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today announced that on April 30, 2024, the company granted equity awards to ten new employees, pursuant to the company’s 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4). The employees rece...
MercadoLibre, Inc. Reports First Quarter 2024 Financial Results Montevideo, May 02, 2024 (GLOBE NEWSWIRE) -- MercadoLibre, Inc. (Nasdaq: MELI) () today reported financial results for the quarter ended March 31, 2024, in a Letter to Shareholders, which is now posted to the company’s Investor Relations website . The Company will host its earnings video conference, as well as a conference call and audio webcast for any questions that investors may have, on May 2, at 5:00 p.m. Eastern Time. To access our video webcast and the live audio, investors, analysts and the market in general may ...
Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor, including on Monte Rosa’s Scientific Advisory Board BOSTON, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Owen Wallace, Ph.D., the Company’s Chief Scientific Officer will be departing from his position to transition to a Chief Executive Officer role at a UK...
Itron Announces First Quarter 2024 Financial Results LIBERTY LAKE, Wash., May 02, 2024 (GLOBE NEWSWIRE) -- Itron, Inc. (NASDAQ: ITRI), which is innovating the way utilities and cities manage energy and water, announced today financial results for its first quarter ended March 31, 2024. Key results for the quarter include (compared with the first quarter of 2023): Revenue of $603 million, increased 22%;Gross profit of $205 million, increased 31%;GAAP net income attributable to Itron, Inc. of $52 million, increased $64 million;GAAP diluted earnings per share of $1.12, increased $1.38 per...
LIBERTY LAKE, Wash.--(BUSINESS WIRE)-- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, has expanded the capabilities of its ® platform in Australia and New Zealand to include NB-IoT communications, enabling the digital transformation for water utilities. Temetra's comprehensive offering includes meter data processing, storage, operational analytics, validation and more. Adding NB-IoT functionality provides water utilities with the flexibility they need to maximize business value and streamline operations on a single platform. Availa...
Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024 Management will also participate in four upcoming investor healthcare conferences SALT LAKE CITY, April 30, 2024 (GLOBE NEWSWIRE) -- . (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its first quarter earnings conference call on Tuesday, May 7, 2024 at 4:30pm ET. The company’s quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company’s performance for the first...
Are the Lows "In" for this Pullback? While we are not yet out of the woods, we continue to see evidence that suggests the lows may be "in" for this pullback. Last week (4/23/24 Compass) we discussed the possibility that further downside was limited on the S&P 500 due to a multitude of reasons (SPX had simply filled 2/22/24 gap support that we had been discussing since late-February, Russell 2000 and Equal-Weighted S&P 500 were holding above key supports, short-term oversold conditions, subdued ...
ALX Oncology Announces Initiation of Phase 2 Investigator-Sponsored Trial of Neoadjuvant Radiation and Evorpacept in Combination with Pembrolizumab in Patients with Untreated HPV-Mediated Oropharyngeal Cancer SOUTH SAN FRANCISCO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored trial (“IST”) of neoadjuvant radiation and evorpacept, a next-generation CD47 bloc...
CECO Environmental Reports First Quarter 2024 Results Reports Record First Quarter Revenue and Gross Margins, Near Record BacklogReaffirms Full Year 2024 Guidance DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- CECO Environmental Corp. (Nasdaq: CECO) ("CECO"), a leading environmentally focused, diversified industrial company whose solutions protect people, the environment, and industrial equipment, today reported its financial results for the first quarter results of 2024. First Quarter Summary(1) Orders of $145.3 millionBacklog of $389.5 million, up 9 percentRevenue of $126.3 million...
MercadoLibre, Inc. to Report First Quarter 2024 Financial Results Montevideo, April 29, 2024 (GLOBE NEWSWIRE) -- MercadoLibre, Inc. to Report First Quarter 2024 Financial Results MONTEVIDEO, Uruguay; April 29, 2024; (GLOBE NEWSWIRE) -- MercadoLibre, Inc. (Nasdaq: MELI) () announces that it intends to release financial results for its first fiscal quarter ending March 31, 2024, on May 2, 2024. The Company will host its earnings results video conference, as well as a conference call and audio webcast, on May 2, at 5:00 p.m. Eastern Time. In order to access our video webcast and...
Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology - Publication highlights administration of setmelanotide therapy resulted in a mean percent reduction in BMI of 15% at 16 weeks and 26% at one year of treatment - - Topline data from ongoing pivotal Phase 3 clinical trial in hypothalamic obesity on track for 2Q 2025 - BOSTON, April 29, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on...
Inotiv, Inc. to Report Fiscal 2024 Second Quarter Financial Results and Host Conference Call on Friday, May 10, 2024 WEST LAFAYETTE, Ind., April 29, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it will issue its financial results for the fiscal 2024 second quarter ended March 31, 2024, on Friday, May 10, 2024, before the opening of the stock market. The C...
LIBERTY LAKE, Wash.--(BUSINESS WIRE)-- Itron, Inc. (NASDAQ: ITRI), which is innovating new ways for utilities and cities to manage energy and water, is collaborating with (Council), located in Queensland, Australia, to deploy Itron’s intelligent connectivity and analytic solution, which includes and the utility’s existing mesh network technology that utilizes Itron’s unified for data collection and data management. The Itron solution will be deployed over the next three years as part of Council’s comprehensive water security plan to take advantage of technology to better identify water leak...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.